Unlocking Global Partnerships: How Korean Biotech Can Thrive in 2026
- 2026.10.21
- 183
Park Young-min, head of the Korea Drug Development Fund (KDDF), emphasized the critical role of global partnerships in transforming promising research into tangible drug developments. He stressed that domestic biotech firms must secure development capabilities and explore new business opportunities through collaborations with global pharmaceutical companies to successfully commercialize their technologies.
On Monday, KDDF hosted the 2026 KDDF CPG Symposium at the Westin Chosun Seoul. The event attracted representatives from major pharmaceutical companies like Boehringer Ingelheim, Astellas, and Bayer, who shared their external innovation strategies and collaboration success stories.
In his opening address, Park stated that to turn promising scientific discoveries into successful medicines, it needs robust global partnerships and capabilities. It hopes this dialogue fosters understanding between Korean biotech companies and global partners, paving the way for new collaborations and concrete results.